Scipher Medicine, a Waltham, MA-based developer of a molecular technology platform that can predict if a patient will actually respond to a particular drug therapy, completed its Series A funding round.
The round, led by Khosla Ventures, brought total funds raised by the company to date to $10m.
Led by CEO Alif Saleh, Scipher Medicine has developed a platform that interprets RNA or protein expression data from a patient’s blood or tissue sample to reveal the underlying molecular process regulating the disease, generating a patient specific disease signature. Drugs are then screened to determine which therapy actually targets the disease signature in order to accurately predict patient response. The platform addresses both diagnostic and therapeutic opportunities by predicting drug response and identifying opportunities for new drug development.
The company’s co-founders are:
– Dr. Joseph Loscalzo, Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, Chairman of the Department of Medicine, and Physician-in-Chief at Brigham and Women’s Hospital and
– Dr. Albert-Laszlo Barabasi, Robert Gray Dodge Professor of Network Science and a Distinguished University Professor at Northeastern University.